Changsha, China – From September 23 to September 25, Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort® EP") and MicroPort Sorin CRM (Shanghai) Co., Ltd. ("MSC") attended 12th Biennial Congress of Chinese Society of Pacing and Electrophysiology. Held in Changsha of Hunan Province, the congress showed the achievements of fundamental and clinical researches in the field of arrhythmias, as well as advancement in the diagnosis and treatment of arrhythmias and the industry of cardiac electrophysiology and pacemaker. In the congress, the two companies displayed innovative products such as Columbus® 3D EP Navigation System ("Columbus®") and hosted satellite meetings which attracted wide attention.
On September 23, MicroPort® EP hosted a satellite meeting themed "Columbus®: Navigation for the Heart." The meeting was co-chaired by Professor Congxin Huang, who is Chairman of the Society of Cardioelectrophysiology and Pacing of Chinese Medical Association, Head of Wuhan University Cardiovascular Disease Research Center, and President of Renmin Hospital of Wuhan University, Professor Zulu Wang from the General Hospital of Shenyang Military, Professor Minglong Chen from Jiangsu Province Hospital, and Professor Xuewen Li from Shanxi Dayi Hospital. Professor Ribo Tang from Beijing Anzhen Hospital of Capital Medical University, Professor Bing Han from Xuzhou Central Hospital, Professor Li Su from the Second Affiliated Hospital of Chongqing Medical University, and Professor Ming Liang from the General Hospital of Shenyang Military, were invited as key note speakers in the satellite meeting, shared the clinical outcome and application of Columbus® 3D EP Navigation System ("Columbus®") and PathBuilder™ Interatrial Septal Puncture, a new product of MicroPort® EP waiting for approval from CFDA.
In the beginning of the meeting, Professor Congxin Huang introduced the rapid development of domestically developed medical devices in recent years, and expressed his expectation on the emerging of more domestically made medical devices with breakthrough innovations to benefit patient with arrhythmias in China. Meanwhile, Professor Minglong Chen pointed out, only through the integration of bioscience, physical science and engineering science can high-quality medical device be developed to satisfy the clinical requirement.
Afterwards, Professor Ribo Tang reported the result of the Multi-center, Controlled Clinical Trial of Columbus® in the treatment of persistent atrial fibrillation. It shows the success rate of intra-operative pulmonary vein isolation in the radiofrequency ablation with Columbus® is 100%, and the radiofrequency ablation with Columbus® achieved higher one-year success rate of 67.1% compared to that of 22.8% for antiarrhythmic oral medication, a mainstream treatment of persistent atrial fibrillation. It means Columbus® has reached China's highest level and is as good as imported medical devices in terms of success rate.
Professor Bing Han shared his experience in successfully ablating a complex atrial flutter using Columbus®, and noted that in addition to ablation treatment of persistent atrial fibrillation, Columbus® is also capable of dealing with complex tachyarrhythmias such as atrial tachycardia, complex atrial flutter and ventricular arrhythmias with its excellent mapping capacity. As one of the first surgeons who use Columbus®, Professor Li Su summarized cases in the Columbus® Single-center Clinical Trial and shared his experience with the system. He said the outstanding performance and stability of Columbus® also enhanced his confidence in domestic medical devices. Started with the development history of trial septal puncture, Professor Ming Liang introduced the results of the Multi-center Clinical Trial of PathBuilder™ Interatrial Septal Puncture System and shared his clinical experience in using the system. He said, it has excellent safety and efficacy in atrial septal puncture, with 100% successful puncture rate, and meanwhile feels the same as imported products.
In his speech, Professor Zulu Wang recognized the comprehensive product line and the stable product performance of MicroPort® EP. As the surgeon who completed the most Columbus® cases in clinical trials with leading success rate, Professor Wang said Columbus® ranks among the best of domestic EP navigation systems, and he encouraged MicroPort® EP to be the pioneer to provide complete domestic EP solutions to patients and surgeons.
During the congress, MicroPort® EP displayed its whole product line including Columbus®, and many attendees were attracted to visit its booth. Several experts who learnt Columbus® for the first time showed great interest in it and said they looked forward to using it in radiofrequency ablation to treat various kinds of arrhythmias. Meanwhile, MSC hosted a satellite meeting, themed "Striving for Excellence – From SafeR to Disease Management," during the congress. The satellite meeting was chaired by Professor Yangang Su of Zhongshan Hospital of Fudan University, Professor Wei Hua of Fuwai Hospital of Chinese Academy of Medical Sciences, and Professor Jiefu Yang of Beijing Hospital. Director He Huang of Renmin Hospital of Wuhan University and Professor Xingbin Liu of West China Hospital of Sichuan University were invited as key note speakers to lecture on sleep apnea monitor ("SAM") and SafeR functions of cardiac pacing devices, which was well received by attendees.